NK- and T-cell lymphoma · 5 regimens
Cost vs Efficacy · 1 point
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Pembrolizumab monotherapy Variant #01 | — | R 286 955 | 14d | ~5.8 mo | ~15.5 mo | ~13 | ~R 3 730 419 PFS proxy · indirect | 40 |
Fludarabine, Busulfan, Cyclophosphamide, then allo HSCT Variant #01 | — | R 16 788 | — | — | — | — | — | — |
SMILE N/A - secondary systemic drug | — | R 3 002 | 28d | — | — | — | — | — |
AspaMetDex (Erwinaze) Variant #01 | — | R 451 | 21d | — | — | — | — | — |
AspaMetDex Variant #01 | — | R 451 | 21d | — | — | — | — | — |
5 of 5 regimens shown